Join to View Full Profile
34 Park St# ConnectiNew Haven, CT 06519
Phone+1 203-974-7417
Fax+1 203-974-7413
Dr. Woods is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1980 - 1984
Baylor College of MedicineClass of 1978
Certifications & Licensure
CT State Medical License 1984 - 2025
TX State Medical License 1979 - 1984
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Rapid Benzodiazepine Detoxification Using Flumazenil - 1 Start of enrollment: 1993 Jan 01
- Treatment of Panic Disorder: Long Term Strategies Start of enrollment: 1999 Feb 01
- Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics
- Join now to see all
Publications & Presentations
PubMed
- Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.Jean Addington, Lu Liu, Amy Braun, Andrea Auther, Monica E Calkins
Schizophrenia. 2025-04-03 - Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.Nora Penzel, Pablo Polosecki, Jean Addington, Celso Arango, Ameneh Asgari-Targhi
Schizophrenia. 2025-04-03 - Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program.Tashrif Billah, Kang Ik K Cho, Owen Borders, Yoonho Chung, Michaela Ennis
Schizophrenia. 2025-04-03
Journal Articles
- Use of Machine Learning to Determine Deviance in Neuroanatomical Maturity Associated with Future Psychosis in Youths at Clinically High RiskDaniel H Mathalon, Thomas McGlashan, Scott W Woods, Diana Perkins, Ming Tsuang, Carrie E Bearden, Kristin Cadenhead, JAMA
Press Mentions
Feinstein Institutes Researchers Help Lead $52M Study of Schizophrenia in High-Risk YouthNovember 16th, 2020- Accelerating Science to Advance Early Interventions for SchizophreniaOctober 30th, 2020
- Scientists Awarded $52M NIH Grant to Study Schizophrenia Cause and EffectSeptember 15th, 2020
- Join now to see all
Grant Support
- 8/8-Predictors And Mechanisms Of Conversion To PsychosisNational Institute Of Mental Health2008–2012
- Huperzine For Cognitive And Functional Impairment In SchizophreniaNational Institute Of Mental Health2008–2010
- Enhancing The Prospective Prediction Of PsychosisNational Institute Of Mental Health2003–2007
- Tardive Dyskinesia Incidence And Atypical AntipsychoticNational Institute Of Mental Health2001–2004
- Treatment Of Panic Disorder--Long Term StrategiesNational Institute Of Mental Health1999–2003
- Tardive Dyskinesia Incidence And Atypical AntipsychoticsNational Institute Of Mental Health2000
- Atypical Antipsychotic Medications--Outcomes And CostsNational Institute Of Mental Health1997–2000
- Glutaminergic Agents For Cocaine AbuseNational Institute On Drug Abuse1996–1998
- CT DMH Yale Medication Effectiveness Research ProgramNational Institute Of Mental Health1994–1998
- Multictr Comparative Treatment Study Of Panic DisorderNational Institute Of Mental Health1996
- Multi-Ctr Comparative Treatment Study Of Panic DisorderNational Institute Of Mental Health1995
- Treatment Study Of Panic DisorderNational Institute Of Mental Health1994
- Rapid Benzodiazepine Detoxification Using FlumazenilNational Institute On Drug Abuse1993–1994
- Multi-Ctr Comparative Treatment Study Of Panic DisorderNational Institute Of Mental Health1990–1993
- Effects Of Yohimbine On RCBF In Panic DisorderNational Institute Of Mental Health1989
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
